Abiomed (Abiomed) ROCE % : 14.84% (As of Sep. 2022)

View and export this data going back to 1987. Start your Free Trial

What is Abiomed ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abiomed's annualized ROCE % for the quarter that ended in Sep. 2022 was 14.84%.

Abiomed ROCE % Historical Data

The historical data trend for Abiomed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed ROCE % Chart

Abiomed Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

ROCE %

Get a 7-Day Free Trial

26.58

27.25

24.52

18.74

17.70

Abiomed Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial															17.51	18.06	17.33	17.06	14.84

Abiomed ROCE % Calculation

Abiomed's annualized ROCE % for the fiscal year that ended in Mar. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2022 )		(A: Mar. 2021 )		(A: Mar. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2022 )		(A: Mar. 2021 )		(A: Mar. 2022 )
	=	256.706	/	( ( (1494.359 - 128.969)	+	(1673.393 - 138.457) )	/ 2 )
	=	256.706	/	( (1365.39	+	1534.936)	/ 2 )
	=	256.706	/	1450.163
	=	17.70 %

Abiomed's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	231.976	/	( ( (1703.636 - 140.762)	+	(1696.544 - 134.06) )	/ 2 )
	=	231.976	/	( ( 1562.874	+	1562.484 )	/ 2 )
	=	231.976	/	1562.679
	=	14.84 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

Abiomed (NAS:ABMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abiomed ROCE % Related Terms

Thank you for viewing the detailed overview of Abiomed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abiomed (Abiomed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Cherry Hill Drive, Danvers, MA, USA, 01923

Website

https://www.abiomed.com

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

Executives

Matthew T. Plano	officer: VP, GLOBAL OPERATIONS	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter	director	2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber	officer: Chief Operating Officer	2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp	officer: Vice President, CFO	C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue	director, officer: President & CEO	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas	director	ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson	director	22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle	director	1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield	officer: VP Healthcare Solutions	14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began	officer: VP & General Counsel	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley	officer: Vice President	22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt	officer: SVP, DA and QA	C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139